Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960569 | 0.74 | APEX1 (0.50) | HTTEDNRBEDNRACYP2C9 | |
| SCHEMBL9960776 | 0.69 | MAPT (0.36) | MAPTLMNA | |
| SCHEMBL29706093 | 0.68 | HCAR2 (0.50) | HCAR2HDAC3TNKSHDAC4HDAC1 | |
| SCHEMBL9297750 | 0.66 | NFKB1 (0.67) | HCAR2HDAC3TNKSHDAC4HDAC1 | |
| SCHEMBL3404312 | 0.66 | HDAC3 (0.42) | HCAR2HDAC3TNKSHDAC4HDAC1 | |
| SCHEMBL2530115 | 0.66 | AKR1B1 (0.41) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL9960625 | 0.66 | MAPT (0.39) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL27945139 | 0.66 | ALDH1A1 (0.39) | HDAC3HDAC4HDAC7HDAC8HDAC6 | |
| SCHEMBL11811807 | 0.64 | HCAR2 (0.46) | HCAR2HDAC3TNKSHDAC4HDAC1 | |
| SCHEMBL28806317 | 0.63 | ALDH1A1 (0.37) | HDAC4HDAC2HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107653293-B | Preparation method of specific site-hydroxylated ingenane diterpene derivative | 复旦大学 | 2021-01-26 | — | — | CN | disclosed |
| CN-107653293-A | The preparation method of specific site hydroxylating ingane type forskolin | 复旦大学 | 2018-02-02 | — | — | CN | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| EP-2864290-B1 | 3-O-HETEROARYL-INGENOL | LEO LABORATORIES LTD (IE) | 2017-06-14 | — | — | EP | disclosed |
| WO-2017089301-A1 | 3-TRIAZOLO-3-DEOXY-INGENOLS | LEO LABORATORIES LIMITED (IE) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089300-A1 | 3-ALKYLAMIDO-3-DEOXY-INGENOLS | LEO LABORATORIES LIMITED (IE) | 2017-06-01 | — | — | WO | disclosed |
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| WO-2016173651-A1 | FORMULATIONS COMPRISING INGENOL 3-(3,5-DIETHYLISOXAZOLE-4-CARBOXYLATE) | LEO LABORATORIES LIMITED (IE) | 2016-11-03 | — | — | WO | disclosed |
| WO-2013088380-A1 | GEL COMPOSITIONS | LEO LABORATORIES LIMITED (IE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088376-A1 | GEL COMPOSITIONS | LEO LABORATORIES LIMITED (IE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| US-7378445-B2 | Treatment of prostate cancer | PEPLIN RESEARCH PTY. LTD. (AU) | 2008-05-27 | — | — | US | disclosed |
| US-20060105994-A1 | Treatment of prostate cancer | PEPLIN RESEARCH PTY LTD. (AU) | 2006-05-18 | — | — | US | disclosed |
| US-20030171334-A1 | Treatment of prostate cancer | PEPLIN RESEARCH PTY LTD (AU) | 2003-09-11 | — | — | US | disclosed |
| EP-1320376-A2 | TREATMENT OF PROSTATE CANCER | Peplin Research Pty Ltd (AU) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002011743-A2 | TREATMENT OF PROSTATE CANCER | PEPLIN RESEARCH PTY LTD (AU) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | HCAR2 136/4885HDAC3 21/4885TNKS 3709/4885 |
| US-20060105994-A1 | Treatment of prostate cancer | ACP3, KLK3, BPHL | HCAR2 1674/4885HDAC3 1115/4885TNKS 1736/4885 |
| US-20030171334-A1 | Treatment of prostate cancer | ACP3, KLK3, BPHL | HCAR2 1674/4885HDAC3 1115/4885TNKS 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.